Endo and Impax had non-compete agreement, FTC says

A lower court mischaracterised an agreement between Endo Pharmaceuticals and Impax Laboratories to forgo competition over a painkiller as a valid patent licensing agreement, the Federal Trade Commission has argued on appeal before the US Court of Appeals for the District of Columbia Circuit.